With common bacterial pathogens becoming increasingly resistant to the current therapeutic arsenal, there is a growing need to utilize alternative strategies when developing new antibacterial drugs. In this issue of Chemistry & Biology, Smith et al. explore the idea of antivirulence drugs by developing inhibitors of the type IV secretion system in Brucella.